09.08.10
PPD, Inc. has established preferred provider relationships with a network of sites across North America for conducting Phase I trials. The sites include Commonwealth Biomedical Research in Madisonville, KY, CNS Network in Los Angeles and Lovelace Scientific Resources, a subsidiary of Lovelace Respiratory Research, in Albuquerque, NM, Austin, TX, and Sarasota, FL.
These partnerships increase PPD's ability to recruit patients for Phase I trials across a range of therapeutic areas, including cardiovascular, metabolic, respiratory, central nervous system, renal/hepatic disease and biologics. This network also allows PPD to offer integrated services spanning preclinical, Phase I, data management and Phase II-IV clinical development and monitoring services.
"Patient volunteers currently account for approximately 40% of all participants in Phase I studies," said Cindy Doerfler, vice president of PPD's Phase I clinic. "By choosing to build relationships with sites that have demonstrated superior quality and the ability to recruit for various patient populations, we provide our clients a very flexible model for patient enrollment, site location and therapeutic expertise."
According to the company, expanding its Phase I services allows PPD to work more closely with clients in determining early proof-of-concept for compounds and biosimilars, where drugs must go directly into patients. The company is hiring senior project managers in North America to oversee the development of its networks and to manage Phase I trials at these sites. PPD plans to implement this model in other regions such as Central and Eastern Europe and Asia-Pacific.
These partnerships increase PPD's ability to recruit patients for Phase I trials across a range of therapeutic areas, including cardiovascular, metabolic, respiratory, central nervous system, renal/hepatic disease and biologics. This network also allows PPD to offer integrated services spanning preclinical, Phase I, data management and Phase II-IV clinical development and monitoring services.
"Patient volunteers currently account for approximately 40% of all participants in Phase I studies," said Cindy Doerfler, vice president of PPD's Phase I clinic. "By choosing to build relationships with sites that have demonstrated superior quality and the ability to recruit for various patient populations, we provide our clients a very flexible model for patient enrollment, site location and therapeutic expertise."
According to the company, expanding its Phase I services allows PPD to work more closely with clients in determining early proof-of-concept for compounds and biosimilars, where drugs must go directly into patients. The company is hiring senior project managers in North America to oversee the development of its networks and to manage Phase I trials at these sites. PPD plans to implement this model in other regions such as Central and Eastern Europe and Asia-Pacific.